Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting an ongoing international observational program called the Fabry Registry to track routine clinical outcomes in patients diagnosed with Fabry disease. This registry includes all patients regardless of their treatment status and aims to improve understanding of the diseases variability, progression, and natural history, including in female patients. It also supports development of monitoring recommendations, characterization of the Fabry population, and evaluation of the long-term safety and effectiveness of Fabrazyme4. The study features a Fabry Pregnancy Sub-registry, which observes pregnancy outcomes in women enrolled in the main registry. This sub-registry collects data on medical and obstetric history, pregnancy, birth outcomes, and infant growth up to 36 months postpartum. Neither the main registry nor the pregnancy sub-registry involve experimental interventions, and patients receive standard care as determined by their treating physicians. Participants undergo clinical assessments and receive their usual care during the registry. Data collected includes safety and effectiveness of treatments like Fabrazyme4 over long periods, as well as pregnancy complications and infant growth measurements. The study is designed to last until 2034, with ongoing monitoring and data collection to support patient care and research without altering treatment plans.
Actively Recruiting
This trial investigates whether tuberculosis preventive treatment TPT given during the window period after exposure can reduce new tuberculosis infections in children and adolescents who live with someone newly diagnosed with pulmonary tuberculosis. The study compares the rate of new infections, measured by IGRA Interferon-Gamma Release Assay conversion at 12 weeks, between those who receive immediate preventive treatment and those who receive standard care where treatment is only given if infection is detected. The goal is to better prevent tuberculosis infection and contribute to global elimination efforts. Participants are assigned to one of two groups. In the intervention group, all children and adolescents receive weekly doses of isoniazid and rifapentine for 12 weeks regardless of their initial IGRA test results. In the control group, only those who test positive on the IGRA test at the start receive this 12-week treatment. Those in the control group who convert to IGRA-positive during the study will also receive treatment following standard care guidelines. During the study, all participants will have IGRA testing at enrollment and again after 12 weeks to detect new infections. Researchers will monitor treatment effects and adverse events related to the 3HP regimen, as well as measure changes in immune response levels. The study lasts 12 weeks with close follow-up to assess the incidence of tuberculosis infection and the safety of the preventive treatment in this young population.